Last reviewed · How we verify
BAX326
BAX326 is a monoclonal antibody targeting CD19.
BAX326 is a monoclonal antibody targeting CD19. Used for Relapsed or refractory B-cell non-Hodgkin lymphoma.
At a glance
| Generic name | BAX326 |
|---|---|
| Also known as | BAX 326, RIXUBIS |
| Sponsor | Baxalta now part of Shire |
| Drug class | Monoclonal antibody |
| Target | CD19 |
| Modality | Biologic |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
BAX326 works by binding to CD19 on the surface of B cells, marking them for destruction by the immune system. This mechanism is thought to be effective in treating certain types of blood cancers.
Approved indications
- Relapsed or refractory B-cell non-Hodgkin lymphoma
Common side effects
- Neutropenia
- Thrombocytopenia
- Anemia
Key clinical trials
- RIXUBIS Drug Use-Result Survey (Japan)
- RIXUBIS PMS India (RIXUBIS PMS) (PHASE4)
- BAX 326 (rFIX) Continuation Study (PHASE3)
- Pivotal Study (Pharmacokinetics, Efficacy, Safety) of BAX 326 (rFIX) in Hemophilia B Patients (PHASE3)
- BAX 326 Pediatric Study (PHASE2, PHASE3)
- BAX 326 Surgery Study in Hemophilia B Patients (PHASE3)
- Post-Marketing Surveillance (Usage Results Study) of RIXUBIS in Adult and Pediatric Patients With Haemophilia B in South Korea
- IMMUNINE Pre-Treatment Study (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- BAX326 CI brief — competitive landscape report
- BAX326 updates RSS · CI watch RSS
- Baxalta now part of Shire portfolio CI